Login to Your Account



Dyax deal vindicated: Shire's HAE drug proves mettle in pivotal phase III

By Marie Powers
News Editor

Thursday, May 18, 2017

Eighteen months after picking up Dyax Corp. for $5.9 billion in cash, Shire plc appears to have a winner with lanadelumab, originally known as DX-2930. The plasma kallikrein inhibitor, which Shire first designated as SHP-643, met its primary and secondary endpoints with highly statistical significance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription